Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Jan;70(1):570–575. doi: 10.1128/jvi.70.1.570-575.1996

Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220.

J E Tanner 1, C Alfieri 1, T A Chatila 1, F Diaz-Mitoma 1
PMCID: PMC189846  PMID: 8523572

Abstract

The cellular receptor for Epstein-Barr virus (EBV) is the type 2 complement receptor, CD21. At initial infection, EBV virion glycoproteins gp350 and gp220 bind to CD21. We report here that the cross-linking of CD21 by gp350/220 results in increased amounts of interleukin 6 (IL-6) RNA and IL-6 protein. This effect could be blocked with anti-gp350/220 and anti-CD21 monoclonal antibodies. Induction of IL-6 in B cells by EBV could be mimicked by treatment with the protein kinase C (PKC) activator phorbol 12,13-dibutyrate but not with the calcium ionophore ionomycin. IL-6 induction by EBV was inhibited with the PKC-specific inhibitor bisindolylmaleimide or the protein tyrosine kinase inhibitors methyl 2,5-dihydroxycinnamate and herbimycin A, indicating that the induction of IL-6 following CD21 cross-linking is mediated through PKC- and protein tyrosine kinase-dependent pathways.

Full Text

The Full Text of this article is available as a PDF (224.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. doi: 10.1016/s0065-2776(08)60532-5. [DOI] [PubMed] [Google Scholar]
  2. Alfieri C., Birkenbach M., Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 1991 Apr;181(2):595–608. doi: 10.1016/0042-6822(91)90893-g. [DOI] [PubMed] [Google Scholar]
  3. Carter R. H., Fearon D. T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992 Apr 3;256(5053):105–107. doi: 10.1126/science.1373518. [DOI] [PubMed] [Google Scholar]
  4. Carter R. H., Spycher M. O., Ng Y. C., Hoffman R., Fearon D. T. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol. 1988 Jul 15;141(2):457–463. [PubMed] [Google Scholar]
  5. Cheung R. K., Dosch H. M. The tyrosine kinase lck is critically involved in the growth transformation of human B lymphocytes. J Biol Chem. 1991 May 15;266(14):8667–8670. [PubMed] [Google Scholar]
  6. Demaret J. P., Brunie S., Ballini J. P., Vigny P. Geometry of intercalation of psoralens in DNA approached by molecular mechanics. Photochem Photobiol. 1989 Jul;50(1):7–21. doi: 10.1111/j.1751-1097.1989.tb04124.x. [DOI] [PubMed] [Google Scholar]
  7. Gold M. R., DeFranco A. L. Biochemistry of B lymphocyte activation. Adv Immunol. 1994;55:221–295. doi: 10.1016/s0065-2776(08)60511-8. [DOI] [PubMed] [Google Scholar]
  8. Gordon J., Ley S. C., Melamed M. D., Aman P., Hughes-Jones N. C. Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus. J Exp Med. 1984 May 1;159(5):1554–1559. doi: 10.1084/jem.159.5.1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gordon J., Walker L., Guy G., Brown G., Rowe M., Rickinson A. Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology. 1986 Aug;58(4):591–595. [PMC free article] [PubMed] [Google Scholar]
  10. Groene W. S., Shaw R. D. Psoralen preparation of antigenically intact noninfectious rotavirus particles. J Virol Methods. 1992 Jul;38(1):93–102. doi: 10.1016/0166-0934(92)90172-a. [DOI] [PubMed] [Google Scholar]
  11. Hoffman G. J., Lazarowitz S. G., Hayward S. D. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980 May;77(5):2979–2983. doi: 10.1073/pnas.77.5.2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Izquierdo M., Cantrell D. A. Protein tyrosine kinases couple the interleukin-2 receptor to p21ras. Eur J Immunol. 1993 Jan;23(1):131–135. doi: 10.1002/eji.1830230121. [DOI] [PubMed] [Google Scholar]
  13. Janicot M., Flores-Riveros J. R., Lane M. D. The insulin-like growth factor 1 (IGF-1) receptor is responsible for mediating the effects of insulin, IGF-1, and IGF-2 in Xenopus laevis oocytes. J Biol Chem. 1991 May 25;266(15):9382–9391. [PubMed] [Google Scholar]
  14. Katira A., Knox K. A., Finney M., Michell R. H., Wakelam M., Gordon J. Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40. Clin Exp Immunol. 1993 May;92(2):347–352. doi: 10.1111/j.1365-2249.1993.tb03403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kawakami T., Inagaki N., Takei M., Fukamachi H., Coggeshall K. M., Ishizaka K., Ishizaka T. Tyrosine phosphorylation is required for mast cell activation by Fc epsilon RI cross-linking. J Immunol. 1992 Jun 1;148(11):3513–3519. [PubMed] [Google Scholar]
  16. Kuruvilla A., Putcha G., Poulos E., Shearer W. T. Tyrosine phosphorylation of phospholipase C concomitant with its activation by platelet-activating factor in a human B cell line. J Immunol. 1993 Jul 15;151(2):637–648. [PubMed] [Google Scholar]
  17. Luxembourg A. T., Cooper N. R. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J Immunol. 1994 Nov 15;153(10):4448–4457. [PubMed] [Google Scholar]
  18. Martin D. R., Yuryev A., Kalli K. R., Fearon D. T., Ahearn J. M. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J Exp Med. 1991 Dec 1;174(6):1299–1311. doi: 10.1084/jem.174.6.1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Matsumoto A. K., Martin D. R., Carter R. H., Klickstein L. B., Ahearn J. M., Fearon D. T. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med. 1993 Oct 1;178(4):1407–1417. doi: 10.1084/jem.178.4.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Morrissey J. H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981 Nov 1;117(2):307–310. doi: 10.1016/0003-2697(81)90783-1. [DOI] [PubMed] [Google Scholar]
  21. Murphy L. D., Herzog C. E., Rudick J. B., Fojo A. T., Bates S. E. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990 Nov 13;29(45):10351–10356. doi: 10.1021/bi00497a009. [DOI] [PubMed] [Google Scholar]
  22. Oyaizu N., McCloskey T. W., Than S., Hu R., Kalyanaraman V. S., Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood. 1994 Oct 15;84(8):2622–2631. [PubMed] [Google Scholar]
  23. Rickinson A. B., Murray R. J., Brooks J., Griffin H., Moss D. J., Masucci M. G. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv. 1992;13:53–80. [PubMed] [Google Scholar]
  24. Sargeant P., Farndale R. W., Sage S. O. ADP- and thapsigargin-evoked Ca2+ entry and protein-tyrosine phosphorylation are inhibited by the tyrosine kinase inhibitors genistein and methyl-2,5-dihydroxycinnamate in fura-2-loaded human platelets. J Biol Chem. 1993 Aug 25;268(24):18151–18156. [PubMed] [Google Scholar]
  25. Savoie A., Perpête C., Carpentier L., Joncas J., Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. 1994 May 1;83(9):2715–2722. [PubMed] [Google Scholar]
  26. Schick M. R., Nguyen V. Q., Levy S. Anti-TAPA-1 antibodies induce protein tyrosine phosphorylation that is prevented by increasing intracellular thiol levels. J Immunol. 1993 Aug 15;151(4):1918–1925. [PubMed] [Google Scholar]
  27. Tanner J. E., Menezes J. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease. Blood. 1994 Dec 1;84(11):3956–3964. [PubMed] [Google Scholar]
  28. Tanner J. E., Tosato G. Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood. 1992 Jan 15;79(2):452–459. [PubMed] [Google Scholar]
  29. Tanner J., Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest. 1991 Jul;88(1):239–247. doi: 10.1172/JCI115283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tanner J., Weis J., Fearon D., Whang Y., Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987 Jul 17;50(2):203–213. doi: 10.1016/0092-8674(87)90216-9. [DOI] [PubMed] [Google Scholar]
  31. Tanner J., Whang Y., Sample J., Sears A., Kieff E. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J Virol. 1988 Dec;62(12):4452–4464. doi: 10.1128/jvi.62.12.4452-4464.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Tedder T. F., Clement L. T., Cooper M. D. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol. 1984 Aug;133(2):678–683. [PubMed] [Google Scholar]
  33. Tedder T. F., Zhou L. J., Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994 Sep;15(9):437–442. doi: 10.1016/0167-5699(94)90274-7. [DOI] [PubMed] [Google Scholar]
  34. Thorley-Lawson D. A., Mann K. P. Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med. 1985 Jul 1;162(1):45–59. doi: 10.1084/jem.162.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tosato G., Jones K., Breinig M. K., McWilliams H. P., McKnight J. L. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest. 1993 Jun;91(6):2806–2814. doi: 10.1172/JCI116523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tosato G., Tanner J., Jones K. D., Revel M., Pike S. E. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol. 1990 Jun;64(6):3033–3041. doi: 10.1128/jvi.64.6.3033-3041.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991 Aug 25;266(24):15771–15781. [PubMed] [Google Scholar]
  38. Tsokos G. C., Lambris J. D., Finkelman F. D., Anastassiou E. D., June C. H. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J Immunol. 1990 Mar 1;144(5):1640–1645. [PubMed] [Google Scholar]
  39. Uehara Y., Hori M., Takeuchi T., Umezawa H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol. 1986 Jun;6(6):2198–2206. doi: 10.1128/mcb.6.6.2198. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES